Company profile
Ymmunobio AG
Ymmunobio has identified a new tumor marker with superior properties: 1. It is present in at least 13 solid tumors 2. It has a prevalence of up to 95% in cancer patients 3. It is not expressed by normal tissue Ymmunobio has built a complete development program around this novel target featuring three therapeutic antibodies: 1. YB-800ADC, an ADC with linkers of the 3rd generation 2. YB-800R1, a radiopharmaceutical in collaboration with the Paul Scherrer Institute (PSI), Switzerland 3. YB-800BS1, a bi-specific antibody with an aCD3 T-cell engager In addition, Ymmunobio is also developing two companYmmunobio functions as a completely virtual company and has raised CHF 1.32M to date. Our team consists of very experienced Subject Matter Experts who have been working in the industry for decades.
Source: startup.ch
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
